J. Machiels Et Al. , "KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)," 43rd ESMO Congress (ESMO) , vol.29, Munich, Germany, pp.398, 2018
Machiels, J. Et Al. 2018. KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC). 43rd ESMO Congress (ESMO) , (Munich, Germany), 398.
Machiels, J., Licitra, L., Tao, Y. G., Yen, C., Rischin, D., Waldron, J. N., ... Burtness, B. A.(2018). KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC) . 43rd ESMO Congress (ESMO) (pp.398). Munich, Germany
Machiels, J-P. Et Al. "KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)," 43rd ESMO Congress (ESMO), Munich, Germany, 2018
Machiels, J-P. Et Al. "KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)." 43rd ESMO Congress (ESMO) , Munich, Germany, pp.398, 2018
Machiels, J. Et Al. (2018) . "KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)." 43rd ESMO Congress (ESMO) , Munich, Germany, p.398.
@conferencepaper{conferencepaper, author={J-P. Machiels Et Al. }, title={KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)}, congress name={43rd ESMO Congress (ESMO)}, city={Munich}, country={Germany}, year={2018}, pages={398} }